Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1) : a multicentre, randomised, phase 2 trial

MLA

Labori, Knut Jørgen, et al. Neoadjuvant FOLFIRINOX versus Upfront Surgery for Resectable Pancreatic Head Cancer (NORPACT-1) : A Multicentre, Randomised, Phase 2 Trial. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1428105901&authtype=sso&custid=ns315887.

APA

Labori, K. J., Bratlie, S. O., Andersson, B., Angelsen, J.-H., Biörserud, C., Björnsson, B., Bringeland, E. A., Elander, N., Garresori, H., Grønbech, J. E., Haux, J., Hemmingsson, O., Gustafsson Liljefors, M., Myklebust, T. A., Nymo, L. S., Peltola, K., Pfeiffer, P., Sallinen, V., Sandström, P., … Yaqub, S. (2024). Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1) : a multicentre, randomised, phase 2 trial.

Chicago

Labori, Knut Jørgen, Svein Olav Bratlie, Bodil Andersson, Jon-Helge Angelsen, Christina Biörserud, Bergthor Björnsson, Erling Audun Bringeland, et al. 2024. “Neoadjuvant FOLFIRINOX versus Upfront Surgery for Resectable Pancreatic Head Cancer (NORPACT-1) : A Multicentre, Randomised, Phase 2 Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1428105901&authtype=sso&custid=ns315887.